CN1196940A - Compound Chinese and western medicinal compsn. for treating 'upper elimination' diabetes - Google Patents
Compound Chinese and western medicinal compsn. for treating 'upper elimination' diabetes Download PDFInfo
- Publication number
- CN1196940A CN1196940A CN 97107198 CN97107198A CN1196940A CN 1196940 A CN1196940 A CN 1196940A CN 97107198 CN97107198 CN 97107198 CN 97107198 A CN97107198 A CN 97107198A CN 1196940 A CN1196940 A CN 1196940A
- Authority
- CN
- China
- Prior art keywords
- parts
- diabetes
- chinese
- radix
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese and Western medicines composition in the form of capsules for treating "frequently drinking water" type of diabetes uses raw materials such as glibenclamide (0.25-0.35 Wt.%), genseng powder (14-20), straight ladybell root powder (14-20) and Chinese-medicinal extract including 6 Chinese-medicinal materials and features durable curative effect and low toxic by-effect.
Description
The present invention relates to a kind of medicine series for the treatment of diabetes.
Diabetes are a kind of common endocrine-metabolic diseases, its sickness rate has the trend that increases year by year, be listed in the third-largest disease after cardiovascular disease and tumor in developed country, deadly and the disability rate of diabetes and complication thereof has become world medicine man stubborn problem, annual countries in the world are expended huge fund this disease are studied, but produce little effect.The domestic and international chemical synthetic drug that adopts is treated its diabetes at present, its short term effect is satisfied, late result is not fully up to expectations, and the defective that toxic and side effects is big etc., as: phenformin is for a long time with easily producing the lactate acidemia, serious adverse reactions such as ketonemia, countries such as the present U.S. have banned use of biguanides; Often curative effect is better in just with several weeks for sulfonylureas (tolbutamide, glibenclamide), and using had 10～15% patients to lose curative effect suddenly after 6～12 months, and reason is not bright, and the old excellent easy generation of person serious ketoacidosis can take place causes death; Insulin with producing antibody, the increase of biological activity reduction dosage, can cause that then machine-processed compensation response----can cause hyperinsulinemia and blood glucose fluctuation for a long time.To go up a disadvantage in order overcoming, actively to seek solution route both at home and abroad at present from traditional Chinese medical science prescription face.
The traditional Chinese medical herbal treatment diabetes have history remote, and the traditional Chinese medical science claims that diabetes are ＂ diabetes ＂, and are divided into the ＂ that disappears among disappear on the ＂ ＂, the ＂, ＂ diabetes due to kidney-deficiency ＂ three types according to the primary and secondary difference of symptom performance.＂ disappear on the ＂ based on polydipsia, polyuria, polyphagia takes second place; ＂ disappear among the ＂ based on polyphagia, and the polydipsia polyuria takes second place; ＂ diabetes due to kidney-deficiency ＂ is based on polyuria, and the polydipsia polyphagia takes second place.Traditional treatment by Chinese herbs, and the doctor need be according to the dialectical evolution of different patients, very inconvenient, and patient is also very time-consuming bothersome when taking, and prescription drugs can not satisfy need of industrial production, Gu also be difficult to satisfy a large amount of patients' demand.Remember domestic clinical also have adopt Chinese medicine to treat, but these Chinese patent medicines general all general be applied to diabetes (diabetes), so poor effect.(include the Radix Astragali, Radix Ginseng, pollen as the Radix Ginseng metformin that uses clinically, the Radix Rehmanniae, Radix Ophiopogonis, the Rhizoma Anemarrhenae, Gypsum Fibrosum, Poria, Rhizoma Dioscoreae, Radix Glycyrrhizae, Cortex Lycii, Stigma Maydis) it generally is used for treating diabetes, its effective percentage only is 63.3% and (sees the Kuang Anzong chief editor, Hunan science tech publishing house publishes " diabetes are in China " P:279), and according to the tcm syndrome differentiation and typing treatment, curative effect is then also low.Clinical present employed diabetes pill (includes Radix Astragali 5%, the Radix Rehmanniae 15%, pollen 24%, every ball also contains glyburide 0.25mg) also be the Chinese medicine and western medicine compound preparation, because of it was developed in the sixties, according to its prescription as can be known, be applicable to that mainly diabetes initial stage or diabetes ＂ upper elimination type ＂ just can get a desired effect.In the diabetes generaI investigation as for present stage, because of living standard improves, the health medical treatment system improves, the average life span generally prolongs, clinical this type of patient at least 80% has entered middle and advanced stage, and all with cardiovascular complications in various degree, from having made the subject range of diabetes pill.
The objective of the invention is to overcome above-mentioned shortcoming, on the prescription dosage form design, based on motherland's medical science to the diabetes three types of diabetes theory of dividing and ruling, check weighing is to the characteristics of ＂ upper elimination type ＂ deficiency of both QI and YIN, a kind of ＂ upper elimination type ＂ diabetics that is adapted to especially is provided, and the curative effect height, toxic and side effects little by chemical synthetic drug with the vegetable Chinese herbal medicine be compound recipe Chinese and western medicinal composition----the compound diabetes-treating capsule that forms of material combination I number.
Technical scheme of the present invention is finished like this: the compound recipe Chinese and western medicinal composition of treatment ＂ upper elimination type ＂ diabetes includes following raw materials in percentage by weight:
Glibenclamide 0.25%～0.35%, the Radix Ginseng powder 14%～20%, Radix Adenophorae (Radix Glehniae) powder 14%～20%, Chinese medical concrete 59.65%～71.75%, this Chinese medical concrete is made by the following weight proportion raw material: 25～35 parts of Cortex Lycii, 5～15 parts of the Radixs Astragali, 5～15 parts of Radix Ophiopogonis, 5～15 parts of Rhizoma Polygonatis, 5～15 parts of Fructus Schisandrae Chinensis, 5～15 parts of Stigma Maydis.
The present invention has the following advantages: the prescription composition is seted forth one's views in the Western medicine differential diagnosis of diseases, Chinese medicine is dialectical, the Chinese and western medical combination, by modern high tech method, fine condesation and suitable select, effectively carrying out dosage form improves, thereby become a kind of small amount and special effect, exempt to fry in shallow oil easy clothes, carry taking convenience, can take for a long time for this type of patient, become a kind of novel form of specially controlling Shangxiao type diabetes.
Its Chinese and western medicinal composition be also advantageous in that the synergism that compatibility produced between the each component, Western medicine takes stopgap measures fast, and Chinese medicine effects a permanent cure, and has adapted to the needs of ＂ upper elimination type ＂ diabetics homeostasis, its ＂ polydipsia ＂ symptom obviously alleviates, and blood glucose, blood fat also obviously reduce.
On theory of Chinese medical science, based on pathogenetic understanding and the Therapeutic Principle of ancestral's medical science to diabetes, confirm to have sure blood sugar lowering, blood fat reducing, blood pressure lowering, vessel softening, delay comprehensive function such as body aging through modern pharmacology, lay particular emphasis on again have quench the thirst, moisturize, the vegetable Chinese herbal medicine of heat clearing away, yin nourishing function is dialectical and effect a permanent cure; Assistant activates sick islet tissue with the microchemistry compound glibenclamide speed that sure blood sugar reducing function is arranged, and recovers secretion endogenous islets of langerhans to take stopgap measures; The combination of Chinese and Western medicine, Chinese medicine and western medicine is had complementary advantages, and adds effective dosage form improvement, thereby overcome traditional western medicines in treatment diabetes, the dosage of drug is big, decoction inconvenience, though chemosynthesis medicine treatment diabetes have specially good effect, toxic and side effects is big, the disadvantage of normal catastrophic failure after use a period of time.Novel form of the present invention can be controlled blood, level of sugar effectively when stressing to solve diabetes polydipsia symptom, reach the comprehensive General Symptoms that improves, and can stop or the generation of delaying complications of diabetes, reaches in the recent period and takes stopgap measures fast, the intended purposes of effecting a permanent cure long term.
The embodiment of the invention is as follows: the compound recipe Chinese and western medicinal composition of treatment " upper elimination type " diabetes comprises following raw materials in percentage by weight: glibenclamide 0.25%～0.35%, the Radix Ginseng powder 14%～20%, Radix Adenophorae (Radix Glehniae) powder 14%～20% Chinese medicine is invaded cream 59.65%～71.75%, this Chinese medical concrete is made by the following weight proportion raw material: 25～35 parts of Cortex Lycii, 5～15 parts of the Radixs Astragali, 5～15 parts of Radix Ophiopogonis, 5～15 parts of Rhizoma Polygonatis, 15～25 parts of Fructus Schisandrae Chinensis, 15～25 parts of Stigma Maydis.
The optimum weight ratio range of preparation Chinese medical concrete is: 28～32 parts of Cortex Lycii, 8～12 parts of the Radixs Astragali, 8～12 parts of Radix Ophiopogonis, 8～12 parts of Rhizoma Polygonatis, 18～22 parts of Fructus Schisandrae Chinensis, 18～22 parts of Stigma Maydis.
Its preparation method is: at first prepare Chinese medical concrete, take by weighing each component chopping of Chinese herbal medicine by the proportioning in the prescription of the present invention, add water to submerge, soak and decocted 1～2 hour after 2～3 hours, filter, leave and take filtrate after, add water, repeated to decoct 1～2 hour, filter twice filtrate of merging, filtrate concentrates with cryogenic vacuum, to the thick paste shape, oven dry, being ground into fine powder, to cross 80～100 mesh sieves stand-by.
Include 0.25～0.35 gram glibenclamide by per 100 grams medicine of the present invention, 14～20 gram Radix Ginseng powder, 14～20 gram Radix Adenophorae (Radix Glehniae) powder; The proportioning of 59～71.75 gram Chinese medical concretes takes by weighing each component, and it is stirred.
Aforementioned pharmaceutical compositions is incapsulated,, make every capsules include glibenclamide 1～1.5mg by the every capsules 0.3 gram medicine 1# capsule of packing into, Radix Ginseng powder 45～55mg, Radix Adenophorae (Radix Glehniae) powder 45～55mg, Chinese medical concrete 188.5～209mg, i.e. preparation cost invention medicine (compound diabetes-treating capsule I number)
Now the present invention is operated embodiment in table 1 table 2.
Its table 1 is the proportional quantity of preparation Chinese medical concrete in the table 2.
Table 1
Table 2
Medicine of the present invention is suitable for diabetes type of deficiency of both QI and YIN (upper elimination type) disease to be seen based on the polydipsia symptom, has that polyphagia, polyuria, fatigue and weak, dysphoria with feverish sensation in the chest palms and soles, dry mouth and tougue, the tip of the tongue limit are red concurrently, yellow and thin fur, weak pulse or number or a symptom such as unable.Be mainly used to non-insulin-dependent diabetes mellitus.
Medicine of the present invention can be prepared into various peroral dosage forms such as capsule, tablet, oral liquid or electuary.
The usage and dosage of medicine of the present invention is: oral: each 1～2, and every day three times, taking medicine before meal.General logotype is after three months, look the state of an illness and the dose that cuts down according to the circumstance to maintenance dose (be every day 2～3 times).Still note diet, exercise and mood regulation during keeping treatment.
The therapeutic effect of medicine of the present invention has obtained checking by system's clinical experiment of 100 routine patients.
Its experimental technique is:
1. subjects, type ii diabetes people (meeting the diagnostic criteria of the WHO type ii diabetes) patient who selects to go to a doctor is based on the polydipsia symptom, have polyphagia, polyuria concurrently, other symptom has that fatigue and weak, dysphoria with feverish sensation in the chest palms and soles, dry mouth and tougue, the tip of the tongue limit are red, weak pulse or number or unable.
2. randomized controlled design: with " upper elimination type " diabetic of above-mentioned selection by sex, age, occupation, diabetic duration, diabetes family history, to have or not equilibriums such as concurrent hypertension or coronary heart disease, blood glucose, blood fat be two groups, be defined as test group (48 example) and matched group (52 example) with simple random sampling then, test group is taken each 2 of medicine of the present invention, every day three times, matched group is taken diabetes pill, each 10 balls, every day three times.
Experimental result sees Table 3, table 4:
Table 3: blood glucose (mg/dl) situation of change in two groups of therapeutic processes
*Represent p＜0.01
| After the bimester of the treatment before the treatment | |
| The test group matched group | ??n????x±s?????n?????x±s ?48??210±59????45??172±42?? *??*?52??190±40????50??189±45 |
Table 4: the situation of change of triglyceride (mg/dl) in two groups of research process
| After the bimester of the treatment before the treatment | |
| The test group matched group | ??n???x±s??????n????x±s ?48??184±82????45??161±65? *?52??188±158???50??186±78 |
*Represent P＜0.05
Above experimental result shows, medicine of the present invention all is better than diabetes pill to blood sugar lowering, the lipid-lowering effect of ＂ upper elimination type ＂ diabetics, embody medicine of the present invention and complied with the dialectical Therapeutic Principle who controls that executes, produced the not available good efficacy of the similar compound Chinese patent medicine of existing treatment diabetes.It is 86% that medicine of the present invention is used for the treatment of its effective percentage of ＂ upper elimination type ＂ diabetics, (being total to " clinical disease diagnosis is according to curing the improvement standard " of the revision in 1987 of the PLA General Logistics Department in the criterion of therapeutical effect reference), the effect of agents alleviate diabetics polydipsia symptom of the present invention is significantly better than the remission effect of diabetes pill.Medicine of the present invention was through clinic trial 1 year, and accidental poison is paid effect, as being index with the common ＂ hypoglycemia ＂ reaction of glibenclamide, through 100 examples to blind two according to through X
2Handle its P＜0.01, show that its difference has remarkable meaning, illustrate that curative effect of medication of the present invention is better than the pure chemistry synthetic drug.Showed that simultaneously distinct Chinese characteristics, the combination of Chinese and Western medicine have the extensive studies prospect.
Claims (2)
1. compound recipe Chinese and western medicinal composition for the treatment of ＂ upper elimination type ＂ diabetes, it includes following raw materials in percentage by weight and forms: glibenclamide 0.25%～0.35%, the Radix Ginseng powder 14%～20%, Radix Adenophorae (Radix Glehniae) powder 14%～20% Chinese medical concrete 59.65%～71.75%, this Chinese medical concrete is made by the following weight proportion raw material: 25～3 parts of Cortex Lycii, 5～15 parts of the Radixs Astragali, 5～15 parts of Radix Ophiopogonis, 5～15 parts of Rhizoma Polygonatis, 5～25 parts of Fructus Schisandrae Chinensis, 15～25 parts of Stigma Maydis.
2. according to the described a kind of compound recipe Chinese and western medicinal composition for the treatment of ＂ upper elimination type ＂ diabetes of claim (1), it is characterized in that said Chinese medical concrete is made up of the best proportion raw material of following weight: 28～32 parts of Cortex Lycii, 8～12 parts of the Radixs Astragali, 8～12 parts of Radix Ophiopogonis, 8～12 parts of Rhizoma Polygonatis, 18～22 parts of Fructus Schisandrae Chinensis, 18～22 parts of Stigma Maydis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97107198 CN1063644C (en) | 1997-11-13 | 1997-11-13 | Compound Chinese and western medicinal compsn. for treating 'upper elimination' diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97107198 CN1063644C (en) | 1997-11-13 | 1997-11-13 | Compound Chinese and western medicinal compsn. for treating 'upper elimination' diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1196940A true CN1196940A (en) | 1998-10-28 |
| CN1063644C CN1063644C (en) | 2001-03-28 |
Family
ID=5169374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 97107198 Expired - Fee Related CN1063644C (en) | 1997-11-13 | 1997-11-13 | Compound Chinese and western medicinal compsn. for treating 'upper elimination' diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1063644C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102805818A (en) * | 2011-05-31 | 2012-12-05 | 北大方正集团有限公司 | Hypoglycemic drug and preparation method thereof |
| CN104225285A (en) * | 2013-06-19 | 2014-12-24 | 谢海雄 | Traditional Chinese medicine composition for treating diabetes |
-
1997
- 1997-11-13 CN CN 97107198 patent/CN1063644C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102805818A (en) * | 2011-05-31 | 2012-12-05 | 北大方正集团有限公司 | Hypoglycemic drug and preparation method thereof |
| CN102805818B (en) * | 2011-05-31 | 2013-12-04 | 北大方正集团有限公司 | Hypoglycemic drug and preparation method thereof |
| CN104225285A (en) * | 2013-06-19 | 2014-12-24 | 谢海雄 | Traditional Chinese medicine composition for treating diabetes |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1063644C (en) | 2001-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103083531B (en) | Drug for treating diabetes | |
| CN1305844A (en) | Medicine for treating congestive heart failure | |
| CN102940251A (en) | Health-care food for reducing blood sugar and blood fat | |
| CN113521134B (en) | Traditional Chinese medicine composition for treating type II diabetes and application | |
| CN1053826C (en) | Tonic hypoglycemic capsule and preparing process thereof | |
| CN100493572C (en) | Composition of medication for treating diabetes | |
| CN1159050C (en) | Compound traditional Chinese medicine preparation for treating type 2 diabetes | |
| CN1748760A (en) | Medicine for treating female menstrual disorder (stagnancy of qi and blood stasis) | |
| CN1137720C (en) | Chinese medicine for treating diabetes and its complication | |
| CN1063644C (en) | Compound Chinese and western medicinal compsn. for treating 'upper elimination' diabetes | |
| CN1062751C (en) | Compound Chinese and western medicinal compsn. for treating 'down elimination' diabetes | |
| CN1063645C (en) | Compound Chinese and western medicinal compsn. for treating 'medium elimination' diabetes | |
| CN1066332C (en) | Hypoglycemic compound capsule | |
| CN1054524C (en) | Medicine composition for treating diabetes mellitus | |
| CN102018852A (en) | Ginseng and coptis capsule for quenching thirsty and reducing blood sugar and preparation process | |
| CN1054525C (en) | Medicinal composition for treating diabetes involving lower jiao | |
| CN100339119C (en) | Traditional Chinese medicine prepns. for treating diabete | |
| CN1058403C (en) | A pharmaceutical composition for the treatment of diabetes | |
| CN1381265A (en) | Medicine for treating cholecystitis and its preparing process | |
| CN1052419C (en) | Herb medicine for treating diabetes mellitus | |
| CN1272054C (en) | Medicine for treating diabetes and its preparing process | |
| CN104474103A (en) | Natural plant hypoglycemic agent and preparation method thereof | |
| CN1183933C (en) | Medicine for treating incomplete kidney function and its prepn | |
| CN106606744A (en) | Combination medicament for treating type 2 diabetes mellitus | |
| CN1101213C (en) | Diabetes treating medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |